Chimerix Inc (NASDAQ:CMRX) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 622,600 shares, a drop of 31.8% from the July 31st total of 912,900 shares. Based on an average daily trading volume, of 382,200 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.4% of the company’s stock are short sold.
Large investors have recently bought and sold shares of the company. Deutsche Bank AG lifted its stake in shares of Chimerix by 27.7% during the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock worth $662,000 after buying an additional 55,950 shares during the period. Acadian Asset Management LLC lifted its position in Chimerix by 15.4% during the second quarter. Acadian Asset Management LLC now owns 557,029 shares of the biopharmaceutical company’s stock valued at $2,407,000 after purchasing an additional 74,472 shares during the period. Dimensional Fund Advisors LP lifted its position in Chimerix by 2.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock valued at $6,715,000 after purchasing an additional 56,347 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Chimerix by 18.7% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 443,743 shares of the biopharmaceutical company’s stock valued at $1,917,000 after purchasing an additional 69,867 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new position in Chimerix during the second quarter valued at $67,000. Institutional investors and hedge funds own 61.96% of the company’s stock.
Several equities analysts recently issued reports on the stock. ValuEngine raised shares of Chimerix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright lifted their price objective on shares of Chimerix from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Chimerix has an average rating of “Hold” and a consensus price target of $4.00.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.18). Chimerix had a negative return on equity of 38.70% and a negative net margin of 729.02%. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.30 million. On average, analysts predict that Chimerix will post -1.1 EPS for the current fiscal year.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Read More: Stocks Increasing Dividends
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.